SCHEMBL6035720

SCHEMBL6035720

CCOC(=O)CCc1ccc(OCCCc2cn(-c3ccc(C(F)(F)F)cn3)nc2OCC)c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
HPGD P15428 1/20 0.38
FFAR4 Q5NUL3 2/20 0.37
SYK P43405 3/20 0.37
MAPT P10636 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.34
ROCK2 O75116 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR2 O15552 1/20 0.34
EPHX2 P34913 1/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
TP53 P04637 1/20 0.33
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034650 0.92 FFAR4 (0.43) SMN1; SMN2HPGDFFAR4KDM4ELMNA
SCHEMBL6036033 0.88 FFAR4 (0.39) SMN1; SMN2HPGDFFAR4SYKFFAR1
SCHEMBL6034474 0.85 SMN1; SMN2 (0.39) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6035613 0.85 TP53 (0.41) SMN1; SMN2HPGDFFAR4MAPTKDM4E
SCHEMBL6337740 0.85 PPARA (0.48)
SCHEMBL6035403 0.84 FFAR4 (0.45) FFAR4MAPTFFAR1FFAR2TP53
SCHEMBL6035391 0.84 FFAR4 (0.39) SMN1; SMN2FFAR4MAPTKDM4EFFAR1
SCHEMBL6035545 0.84 FFAR4 (0.39) SMN1; SMN2HPGDFFAR4MAPTKDM4E
SCHEMBL6036172 0.82 FFAR4 (0.38) SMN1; SMN2FFAR4MAPTKDM4EFFAR1
SCHEMBL6035174 0.81 FFAR4 (0.44) FFAR4FFAR1FFAR2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 SMN1; SMN2 4408/4885HPGD 3297/4885FFAR4 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.